Paroxetine
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Prescription selective serotonin reuptake inhibitor (SSRI) approved for major depressive disorder, GAD, panic disorder, social anxiety disorder, OCD, and PTSD. Notable for its potent serotonin reuptake inhibition and anticholinergic activity. Associated with a higher risk of discontinuation syndrome upon abrupt cessation compared to other SSRIs due to its shorter half-life and lack of active metabolites. Dosage must be determined by your prescribing physician.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Prescription selective serotonin reuptake inhibitor (SSRI) approved for major depressive disorder, GAD, panic disorder, social anxiety disorder, OCD, and PTSD. NutriStack rates the supporting evidence as strong. Common adult dosing is 10–60 mg daily (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete sodium, folate. This profile indexes 10 sources.
- Sexual dysfunction
- Weight gain
- Drowsiness
- Concurrent MAOI use (within 14 days)
- Concurrent pimozide or thioridazine use
The bottom line
Evidence rating strong. Most-documented uses: depression symptom relief, anxiety reduction across multiple anxiety disorders, panic attack prevention. 10 sources indexed (2007–2022), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Potently and selectively inhibits serotonin (5-HT) reuptake by blocking SERT. Also has mild norepinephrine reuptake inhibition and notable anticholinergic (muscarinic receptor antagonism) properties, contributing to its side effect profile. Also a potent inhibitor of CYP2D6, leading to clinically significant drug interactions with CYP2D6 substrates (e.g., codeine, tamoxifen, TCAs).10
Dosing & protocol.
Can be taken with or without food. Take at the same time each day, typically in the morning. Do not crush or chew controlled-release tablets.9
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Sodium
SignificantSSRI-induced SIADH can lower serum sodium, especially in older adults and during the first weeks of therapy.
Folate
MildLower folate status is associated with poorer SSRI response and may be reduced in some chronic users through altered one-carbon metabolism.
Full safety detail.
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
4- 1Meta-analysis of acupuncture combined with paroxetine in the treatment of depressionPMIDWang Y, Zhang A, Dilinuer A et al. · American journal of translational research · 2022
Wang Y, Zhang A, Dilinuer A et al.. Meta-analysis of acupuncture combined with paroxetine in the treatment of depression. American journal of translational research. 2022
- 2Effectiveness of Paroxetine for Poststroke Depression: A Meta-AnalysisPMIDLi L, Han Z, Li L et al. · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2020
Li L, Han Z, Li L et al.. Effectiveness of Paroxetine for Poststroke Depression: A Meta-Analysis. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2020
- 3Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysisPMIDZhang D, Cheng Y, Wu K et al. · BMC urology · 2019
Zhang D, Cheng Y, Wu K et al.. Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis. BMC urology. 2019
- 4Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factorsPMIDBar-Oz B, Einarson T, Einarson A et al. · Clinical therapeutics · 2007
Bar-Oz B, Einarson T, Einarson A et al.. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clinical therapeutics. 2007
Reviews & position papers
3- 5A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor SymptomsPMIDDavid PS, Smith TL, Nordhues HC et al. · International journal of women's health · 2022
David PS, Smith TL, Nordhues HC et al.. A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms. International journal of women's health. 2022
- 6A review of paroxetine for the treatment of vasomotor symptomsPMIDSlaton RM, Champion MN, Palmore KB · Journal of pharmacy practice · 2015
Slaton RM, Champion MN, Palmore KB. A review of paroxetine for the treatment of vasomotor symptoms. Journal of pharmacy practice. 2015
- 7A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?PMIDSanchez C, Reines EH, Montgomery SA · International clinical psychopharmacology · 2014
Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?. International clinical psychopharmacology. 2014
Reference material
3- 8Cipriani A et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018.Source linkedPMID
- 9Ballenger JC et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998.Source linkedPMID
- 10Fava GA et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015.Source linkedPMID
Common questions.
Quick answers about Paroxetine, drawn from the data on this page.
What is Paroxetine?
Prescription selective serotonin reuptake inhibitor (SSRI) approved for major depressive disorder, GAD, panic disorder, social anxiety disorder, OCD, and PTSD. Notable for its potent serotonin reuptake inhibition and anticholinergic activity. Associated with a higher risk of discontinuation syndrome upon abrupt cessation compared to other SSRIs due to its shorter half-life and lack of active metabolites. Dosage must be determined by your prescribing physician.
What is Paroxetine used for?
Commonly cited benefits of Paroxetine include: Depression symptom relief; Anxiety reduction across multiple anxiety disorders; Panic attack prevention; Social anxiety improvement; PTSD symptom relief. NutriStack rates the overall evidence as strong.
What is a typical dose of Paroxetine?
A typical adult dose of Paroxetine is 10–60 mg daily (as prescribed by your physician). The commonly recommended form is Tablet or controlled-release tablet. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Paroxetine?
Reported side effects include sexual dysfunction, weight gain, drowsiness, dry mouth, nausea, constipation. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Paroxetine?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Paroxetine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.